Insider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells 15,102 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August J. Troendle sold 15,102 shares of the stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company's stock, valued at $317,162,563.29. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded up $9.51 during midday trading on Wednesday, reaching $397.86. The company had a trading volume of 297,055 shares, compared to its average volume of 251,064. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00. The firm has a market cap of $12.33 billion, a price-to-earnings ratio of 40.56, a price-to-earnings-growth ratio of 1.99 and a beta of 1.38. The company has a fifty day simple moving average of $398.32 and a two-hundred day simple moving average of $328.94.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business's revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.27 EPS. Analysts expect that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RiverPark Advisors LLC bought a new position in shares of Medpace in the 4th quarter valued at approximately $26,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the 4th quarter valued at $26,000. Rise Advisors LLC bought a new stake in Medpace in the 1st quarter valued at $27,000. Mather Group LLC. bought a new stake in Medpace in the 1st quarter valued at $28,000. Finally, FinTrust Capital Advisors LLC bought a new stake in Medpace in the 3rd quarter valued at $30,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MEDP. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and increased their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Guggenheim increased their target price on Medpace from $453.00 to $464.00 and gave the stock a "buy" rating in a research report on Wednesday, April 24th. UBS Group raised Medpace from a "neutral" rating to a "buy" rating and raised their price target for the company from $282.00 to $452.00 in a report on Thursday, February 15th. StockNews.com raised Medpace from a "hold" rating to a "buy" rating in a report on Tuesday, April 23rd. Finally, Robert W. Baird raised their target price on Medpace from $446.00 to $454.00 and gave the company an "outperform" rating in a research note on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $443.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.